34.231.21.105
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Oncology

Niraparib plus anlotinib show promise in platinum-resistant recurrent ovarian cancer

An oral combination of niraparib plus anlotinib demonstrated promising antitumour activity in patients with platinum-resistant recurrent ovarian cancer, according to results of a phase 2 study. In the multicenter, single-arm ANNIE study, 40 patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within 6 months of last...

Read More
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-